Cuize Medicine key facts
as of Oct 2026- Developer of pulmonary therapy medication intended to be used for the perioperative period.
- Cuize Medicine is valued at approximately $83.4M as of Oct 2026 (last reported valuation).
- It has raised $12.6M; the latest was Later Stage VC ($4.6M) in Jun 2025.
- Notable investors include Goldport Capital, Jiangguo Investment Management, Zhejiang Xianju Pharmaceutical Company.
- Status: Privately Held (backing).
Cuize Medicine's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·Watch Cuize Medicine: the Monday email on marks, rounds and moves
Cuize Medicine funding rounds
No funding rounds for Cuize Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Cuize Medicine
3Cuize Medicine valuation
Cuize Medicine's last reported valuation was $83.4 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Cuize Medicine investors
3 investors are on record for Cuize Medicine, including Goldport Capital, Jiangguo Investment Management and Zhejiang Xianju Pharmaceutical Company.
About Cuize Medicine
Developer of pulmonary therapy medication intended to be used for the perioperative period. The company developed a sustained release technology platform and inhalation powder technology platform, enabling to reduce side effects and delivers sustained curative effects without burst release phenomenon to pulmonary patients.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.